BioAtla
BCAB
63 hedge funds and large institutions have $31M invested in BioAtla in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 27 reducing their positions, and 28 closing their positions.
26% more call options, than puts
Call options by funds: $83K | Put options by funds: $66K
2% more capital invested
Capital invested by funds: $30.4M → $31M (+$645K)
0.19% less ownership
Funds ownership: 0.92% → 0.73% (-0.19%)
21% less funds holding
Funds holding: 80 → 63 (-17)
61% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 28
63% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 27
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.69M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$732K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$593K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$321K |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.32M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.12M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$872K |
| 4 |
SAM
Scion Asset Management
Saratoga,
California
|
-$869K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$839K |
BCAB Hedge Fund Activity: Q3 2024 in Review
63 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q3 2024, worth a combined $31M — up 2.1% from $30.4M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of BCAB and 11 opened new positions — a net loss of 17 holders — while 27 trimmed existing stakes and 10 added.
The largest buyer was Millennium Management, adding an estimated $1.69M. The largest seller was Soleus Capital Management, cutting an estimated $2.32M.
- 63 institutional investors held BioAtla (BCAB) as of Q3 2024, down from 80 in Q2 2024.
- Funds reported $31M of BioAtla stock for Q3 2024, up 2.1% quarter-over-quarter.
- 11 funds opened new BioAtla positions in Q3 2024 and 28 closed out, a net change of -17 holders.
- The largest BioAtla buyer in Q3 2024 was Millennium Management, an estimated $1.69M added.
- The largest BioAtla seller in Q3 2024 was Soleus Capital Management, an estimated $2.32M sold.
Based on aggregated 13F filings for Q3 2024.